AIT Therapeutics Reports Financial Results for Three Months Ended March 31, 2018

Jun 14, 2018 8:00am EDT

AIT Therapeutics Reports Positive Top Line Results from its Nitric Oxide in Bronchiolitis (NO-BRO) Pilot Study in Infants

Jun 13, 2018 4:30pm EDT

AIT Therapeutics Announces Change to Fiscal Year End and Financial Results Conference Call and Webcast for the Three Months Ended March 31, 2018

Jun 07, 2018 4:17pm EDT

AIT Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

May 30, 2018 4:30pm EDT

AIT Therapeutics Presented Data from Its Inhaled Nitric Oxide Study in Patients Infected with Mycobacterium Abscessus Complex (MABSC) at the 2018 American Thoracic Society Conference

May 23, 2018 8:30am EDT

AIT Therapeutics to Present Data from Its Inhaled Nitric Oxide Study in Patients Infected with Mycobacterium Abscessus Complex at the 2018 American Thoracic Society Conference

May 15, 2018 4:30pm EDT

AIT Therapeutics Receives Patent Allowance for Delivery of Inhaled Nitric Oxide at Concentrations of at Least 160ppm for Treatment of Bronchiolitis in Infants

Apr 26, 2018 4:30pm EDT

AIT Therapeutics Names Stephen J. DiPalma as Chief Financial Officer

Apr 16, 2018 8:30am EDT

AIT Granted New Patent for Its Nitric Oxide (NO) Generator and Delivery System

Mar 29, 2018 8:30am EDT

AIT Therapeutics Reports Year End 2017 Financial Results

Mar 19, 2018 4:01pm EDT